Cytodyn Inc (CYDY)

[misiu143]

I just listened to CC for lenzilumab , so they happy with the results and primary endpoint , but when question , how they could see results during the trial without taking penalty , they explained that was an adoptive design trial , that allows modifications to the trial / or statistical procedures, without penalty.

So actually from the beginning to the end they new where they SS and this is why they changed 3 times primary endpoint , and end up with one Statistically Significant .

They did this study as they said with often contacts with NIH.

Hmmm.

IMO...